


Boosting workflows on biomarker analytics - early research phase

Sari Häkkinen Head of Bioanalytics, R&D



Content







Communication **EBF Biomarker Strategies** Added a 5th Pillar Marianne Scheel Fjording, on behalf of the EBF How in Orion R&D Adhere to Regulated BA guidelines Secret Annual An SAFETY **Biomarker** R&D phase **Decisions Testing** Communication level change taken from assays vs. biomarker bioanalysis quidelines data




Orion Pharma R&D

• Our vision is to boost the agility and workflows e.g. in biomarker research





- Our proprietary products therapy areas need world-glass biomarker science to succeed
 - Central Nervous Systems
 - Oncology



Orion Pharma R&D Bioanalytics



Quantitative bioanalytics group - responsibilities

- Small and large 'Orion-molecules' and their metabolites mainly from in-vivo PK/TK studies.
- Developing, testing & validating LC-MS/MS and LBA bioanalytical methods.

Last 5-10 years ever growing need for endogenous biomarker analytics (LC-MS/MS)





Brain power and muscle combined with agility of a small biotech.



Our goal is smooth project work and optimized resourcing of 'PK and biomarker' bioanalytics

In Orion laboratory

In CRO laboratories

Non-regulative bioanalytics of Orion 'hits, leads and candidates'

Non-regulative Biomarker analytics in early research (endogenous pharmacodynamic and safety biomarkers)


Regulative Bioanalytics in animal and human studies

Biomarker analytics in clinical studies



Regulative bioanalytics in BE studies






Orion Pharma R&D Biomarkers



Biomarker Scientist will be engaged to project at drug target assessment phase

> As a member of multidisciplinary team provide scientific leadership in translating preclinical hypothesis into a clinical biomarker strategies



Biomarker development workflow

BIOMARKER IDENTIFICATION & VERIFICATION


DISCOVERY STUDIES

FEASIBILITY \$TUDIES

ASSAY **FEASIBILITY STUDIES**

Sample types Platforms & CROs







BIOMARKERS FOR DRUG CANDIDATE DEVELOPMENT









PROTOTYPE **CLINICAL ASSAY DEVELOPMENT**

CLINICAL **ASSAY READY** TO USE

ANALYTICAL VALIDATION

CLINICAL UTILITY

Selection of CROs Selection of Platforms




Teams in R&D projects


'Players' in new 'Biomarker analytics team'

Biomarker scientist, bioanalytics scientist and in vivo/in vitro pharmacology scientist









Biomarker analytics planning & discussions needed.



Roles and responsibilities in 'biomarker analytics team':

Biomarker scientist and/or PK/PD scientist







Workflows in early research phase

Scientists (in projects)

- 1) **Meet and plan** the studies on biomarker issues in bioanalytical point of view
- 2) **Clarify** objectives of the bioanalyses
- 3) **Discuss and understand** the requirements for bioanalytical methods vs. contexts of use of biomarker data

Heads (operational)

- 1) **Support** projects workflows
- 2) Anticipate
- 3) **Prioritize**
- 4) Optimize resourcing



Improved workflow on biomarkers analytics in early research phase







Past

- BM scientist not always involved in project team discussions.
- In-vivo pharmacologist often ideating the biomarkers to measure.
- Discussion on biomarker bioanalytics insufficient.
- Testing needs for biomarker methods unclear, eg. sensitivity, stability, specificity.

Now

- Biomarker analytics team in pilot projects started.
- BM, BA and Pharmacologist plan the BM studies together (sampling, method develoment and testing).
- Suitability of the assay method to answer the research question in focus.

Future

- BM, BA and Pharmacologist involved in all early phase projects BM-discussions → more relevant planning of studies and optimization of BA methods.
- Testing and validation of methods relevant - not 'tick-box' routine.
- Finding more synergies between projects.

Amount of biomarker ideas and their analytics needs in early phase projects is growing.

Our Goal!



Improved workflow on biomarkers analytics in early research phase





Past

Context of use of BM data

Difficult to prioritize, prepare

often missing.

and resource.

Bioanalytics discussion

started in two early phase pilot projects

Now

- Worksflows clarified via pilot projects
- Follow-up & tuning of operational teams

Future

- Clear plans and execution.
- Efficient resourcing.
- Smooth project progression.

Our Goal!

Amount of biomarker ideas and their analytics needs in early phase projects is still growing.



Acknowledgements:

Elina Serkkola, Head Of Biomarkers and Bioinformatics

Alex Dickens, Senior Scientist, Biomarkers

Maarit Pakarinen, Research Scientist, Bioanalytics

Meri Ramela, Senior Scientist, Bioanalytics

Thank you!